Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956808 · ClinicalTrials.gov registry record · NA
Phonak Behind-The-Ear Quality Evaluation
A NA study, sponsored by Sonova.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05956808: Completed NA study, sponsored by Sonova.
NCT05956808 is a NA study that has completed, run by Sonova. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05956808, a NA study, has completed, sponsored by Sonova.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Subjective listening effort and objective speech intelligibility will be evaluated with a new generation of a Phonak BTE (Behind-The-Ear) hearing aid.
Primary Outcome
Sentences are presented to either the left or right side of the participant's head through a speaker that is 1 meter away. Background noise is presented through the remaining seven speakers that are arranged in a circular pattern around the participant. The sentences are presented at varying levels which may be both louder and softer than the fixed level of noise. The SNR50 is the Signal to Noise Ratio (SNR) at which the participant can repeat 50% of the words correctly. For example, an SNR50 of
Interventions
- DEVICE Phonak Naida BTE hearing aid
- DEVICE Phonak Naida legacy BTE hearing aid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2023-08-16 |
| Phase | NA |
What the finished NCT05956808 record still lists
NCT05956808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Phonak Naida BTE hearing aid is the first listed.
NCT05956808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05956808 about?
NCT05956808 is a clinical study titled "Phonak Behind-The-Ear Quality Evaluation". Subjective listening effort and objective speech intelligibility will be evaluated with a new generation of a Phonak BTE (Behind-The-Ear) hearing aid.
What is the current status of trial NCT05956808?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2023-07-17. Estimated completion is 2023-08-16.
What interventions are being tested in trial NCT05956808?
The interventions under investigation include: Phonak Naida BTE hearing aid (DEVICE), Phonak Naida legacy BTE hearing aid (DEVICE).
Who is sponsoring clinical trial NCT05956808?
This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05956808's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI